



Dec 8th, 2020

PeptiDream Inc.

<https://www.peptidream.com>

Ticker Code : 4587 TSE First Section

PeptiDream Announces Strategic Partnership and License Option Agreement with Amolyt Pharma

KANAGAWA, JAPAN – December 8th, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) today announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma (“Amolyt”), whereby both companies will work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist “GHRA” peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endocrine disorder with serious medical complications, to which Amolyt has an option to license the candidates for future clinical development.

Under the terms of the agreement, PeptiDream will be eligible for certain payments associated with the licensing, development, and commercial success of any GHRA product(s), as well as be eligible for certain royalties on future net sales.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies. The potential expansion of our pipeline into acromegaly, where significant unmet needs persist, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases, including our lead clinical candidate, AZP-3601, for hypoparathyroidism, we believe we have the expertise to successfully bring a promising therapy to acromegaly patients in need,” said Thierry Abribat PhD, CEO of Amolyt Pharma.

“We believe Amolyt Pharma is the ideal partner to lead the development of our GHRA peptide candidates and potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by their therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.” said Patrick C. Reid PhD, President & CEO of PeptiDream.

<About Acromegaly>

Acromegaly is a rare chronic endocrine disorder that is typically caused by an adenoma (benign tumor) of the pituitary gland, and that is characterized by excessive production of growth hormone (GH), resulting in abnormally high levels of insulin-like growth factor-1 (IGF-1). Common features include enlargement of the hands, feet and jaw. Comorbidities and medical complications include cardiovascular disease, cardiomyopathy that can potentially lead to heart failure, impaired glucose tolerance with subsequent development of diabetes, hypogonadism, cancer, bone and joint disease, cerebrovascular events, sleep apnea and impaired respiratory function. The mean age of diagnosis is 40-45 years, but it is often diagnosed 4-10 years after onset due to its slow progression. It is estimated that there are 26,000 acromegaly patients in the U.S. and an additional 35,000 in the E.U.

<About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.

Enquiries:**PeptiDream Inc.**

Mie Yamazaki IR & Public Affairs - (Kanagawa)

EMAIL: m-yamazaki@peptidream.com

Amolyt Pharma

Cherilyn Cecchini, M.D.

LifeSci Communications

EMAIL: ccecchini@lifescicomms.com